ViiV Healthcare’s Cabenuva beats daily oral ART in Phase IIIb trial
ViiV Healthcare’s long-acting HIV treatment Cabenuva showed superior rates of viral suppression compared with oral antiretroviral therapy (ART) in adults …
Post
-
-
Eye implant triggers sight improvements in GA at 36-months, pivotal study finds
Science Corporation’s subretinal implant and specialised glasses combination, PRIMA, has been shown to provide durable, long-term gains in vision to …
-
Parkinson’s disease market expected to reach $7.2bn across the 7MM by 2033
The Parkinson’s disease (PD) market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and …
-
AbbVie, Genmab report positive results from Phase III EPCORE DLBCL-2 trial
AbbVie and Genmab have reported positive topline data from the Phase III EPCORE DLBCL-2 trial of epcoritamab combined with standard …
-
First patient dosed in Vial’s Phase Ib trial of IL-13 x TSLP antibody
Clinical-stage biotechnology company Vial has dosed the first patient in its Phase Ib clinical study evaluating interleukin-13 × thymic stromal …
-
Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority
Vaxcyte’s stock has skyrocketed as its invasive pneumococcal disease (IPD) and pneumococcal pneumonia vaccine has met its endpoints in a …
-
Clinical trial experts turn to AI and new partnerships to tackle growing trial complexity
Next month, senior-level speakers from leading pharma companies such as Roche, AstraZeneca and Novartis, along with speakers from emerging biotechs …
-
EADV26: Key late-stage readouts from the conference
In recent years, there has been an explosion in the range of therapies for immunological diseases, with the treatment paradigm …
-
Surrozen secures FDA clearance for SZN-8141 clinical trial
The US Food and Drug Administration (FDA) has cleared Surrozen’s investigational new drug (IND) application for SZN-8141 to begin clinical …
-
Genmab reports Phase I/II data for Rina-S in ovarian cancer
Genmab has reported data from Part C of the Phase I/II RAINFOL-01 trial of rinatabart sesutecan (Rina-S; GEN1184) in patients …
-
Brainomix’s e-Lung shows progression and treatment response in Phase III trial
Brainomix has debuted data from a Phase III progressive pulmonary fibrosis (PPF) study that highlights the ability of its AI-powered …
-
EASD 2026: GLP-1 and SGLT2 treatment lowers mortality in heart failure patients
At the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting, retrospective research was presented that showed initial …
-
EASD 2026: TRIUMPH-2 data puts retatrutide above the incretin ceiling in T2D
On 30 September, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, …
-
EASD 2026: Petrelintide pairs 10.7% weight loss with placebo-like GI tolerability
On September 30, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, …
-
EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses
Regeneron Pharmaceuticals’ Phase II trial of its muscle-preservation drug for patients using glucagon-like peptide-1 receptor agonists (GLP-1RAs) has met its …
